Compare AAT & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | DMRA |
|---|---|---|
| Founded | 1967 | 2011 |
| Country | United States | United States |
| Employees | 208 | 7 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2010 | 2020 |
| Metric | AAT | DMRA |
|---|---|---|
| Price | $25.31 | $29.55 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $19.50 | ★ $43.00 |
| AVG Volume (30 Days) | 455.3K | ★ 779.4K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $436,204,000.00 | N/A |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $315.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $16.50 |
| 52 Week High | $25.34 | $28.76 |
| Indicator | AAT | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 70.84 | 69.73 |
| Support Level | $18.23 | $22.71 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.49 | 2.39 |
| MACD | -0.02 | 0.89 |
| Stochastic Oscillator | 88.95 | 98.26 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.